Skip to main content
Premium Trial:

Request an Annual Quote

Aetna to Cover NxGen MDx Genetic Testing Services

NEW YORK (GenomeWeb) – NxGen MDx said today its genetic screening and noninvasive prenatal testing will be available to Aetna's members as an in-network benefit, starting Feb. 15. 

The decision by Aetna follows a review of NxGen's products' features, such as full-gene sequencing. The health plan is the third-largest in the US with more than 46 million members. It will cover NxGen MDx's testing at a national level. 

NxGen MDx offers testing for up to 120 various genetic disorders. 

Providing in-network access to the company's testing "removes a barrier for many healthcare professionals who have wanted to use our testing in the past," NexGen MDx CFO Kristin Sherman said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.